Syntheses of tetrahydrothiophenes and tetrahydrofurans and studies of their derivatives as melanocortin-4 receptor ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1124-1130

  Tran, Joe A ^a   Chen, Caroline W ^a   Tucci, Fabio C ^a   Jiang, Wanlong ^a   Fleck, Beth A ^a   Chen, Chen ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Binding affinity; Cyclization; Heterocycle; Melanocortin 4 receptor; Piperazinebenzylamine; Stereoisomer; Synthesis; Tetrahydrofuran; Tetrahydrothiophene

Indexed keywords

LIGAND; MELANOCORTIN 4 RECEPTOR; PIPERAZINE DERIVATIVE; TETRAHYDROFURAN DERIVATIVE; TETRAHYDROTHIOPHENE DERIVATIVE;

ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; LIGAND BINDING; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; FURANS; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PIPERAZINES; RECEPTOR, MELANOCORTIN, TYPE 4; THIOPHENES;

EID: 38749120255     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.11.128     Document Type: Article

References (30)

1. Cone R.D. Nat. Neurosci. 8 (2005) 571
2. Yang Y.K. Obes. Rev. 4 (2003) 239
3. Deboer M.D., and Marks D.L. Trends Endocrinol. Metab. 17 (2006) 199
4. Scarlett J.M., and Marks D.L. Expert Opin. Investig. Drugs 14 (2005) 1233
5. Foster A.C., Chen C., Markison S., and Marks D.L. IDrugs 8 (2005) 314
6. Chen C.W., Tran J.A., Jiang W., Tucci F.C., Arellano M., Wen J., Fleck B.A., Marinkovic D., White N.S., Pontillo J., Saunders J., Madan A., Foster A.C., and Chen C. Bioorg. Med. Chem. Lett. 16 (2006) 4800
7. Mutulis F., Yahorava S., Mutule I., Yahorau A., Liepinsh E., Kopantshuk S., Veiksina S., Tars K., Belyakov S., Mishnev A., Rinken A., and Wikberg J.E.S. J. Med. Chem. 47 (2004) 4613
8. Ujjainwalla, F. 230thACS National Meeting, Washington, DC, USA. 2005, MEDI 275.
9. Hosomi A., Matsuyama Y., and Sakurai H. Chem. Commun. (1986) 1073
10. The sulfoxide 17 consisted of about 1:1 S- and R-isomers based on TLC analysis. They were not separated.
11. For experimental detail, see: Chen, C.; Tran, J. A.; Tucci, F. C.; Chen, C. W.; Jiang, W.; Marinkovic, D.; Arellano, M.; White, N. S. WO 2005/040109.
12. 4, filtered, and concentrated in vacuo to afford trans-4-(4-chlorophenyl)-3-tetrahydrothiophenecarboxylic acid (trans-6) (625 mg, 96% yield).
13. Gianturco M.A., Friedel P., and Giammarino A.S. Tetrahedron 20 (1964) 1763
14. Nymann K., and Svendsen J.S. Acta Chem. Scand 52 (1998) 338
15. Park K.H., Kim S.Y., and Chung Y.K. Org. Biomol. Chem. 3 (2005) 395
16. The trans-cis isomers are interchangeable. Hussain S.A.M.T., Ollis W.D., Smith C., and Stoddart J.F. Perkin Transact. 1 (1975) 1480
17. Makosza M., and Judka M. Chemistry 8 (2002) 4234
18. Kuo G.-H., Prouty C., Wang A., Emanuel S., DeAngelis A., Zhang Y., Song F., Beall L., Connolly P.J., Karnachi P., Chen X., Gruninger R.H., Sechler J., Fuentes-Pesquera A., Middleton S.A., Jolliffe L., and Murray W.V. J. Med. Chem. 48 (2005) 4892
19. Lawlor J.M., and McNamee M.B. Tetrahedron Lett. 24 (1983) 2211
20. Nozaki H., Takaya H., and Noyori R. Tetrahedron 22 (1966) 3393
21. Ito K., and Katsuki T. Chem. Lett. (1994) 1857
22. Lo M.M.-C., and Fu G.C. Tetrahedron 57 (2001) 2621
23. Ito K., Yoshitake M., and Katsuki T. Heterocycles 42 (1996) 305
24. Jiang W., Chen C., Marinkovic D., Tran J.A., Chen C.W., Arellano L.M., White N.S., and Tucci F.C. J. Org. Chem. 70 (2005) 8924
25. 4, filtered, and concentrated in vacuo. The product 1-[2-[(1S)-1-(S-tert-butylsulfinylamino)-3-methylbutyl]-4-(trifluoromethyl)phenyl]-4-{[trans-4-(4-chlorophenyl)-tetrahydro-3-thiophenyl]carbonyl}piperazine was obtained by flash column chromatography (hexane/EtOAc 9:1-1:1) as a white foam (319 mg, 43 % yield).The above compound in MeOH (5 mL) was treated with HCl (4.0 M in 1,4-dioxane, 0.2 mL) for 0.5 h and the solution was concentrated in vacuo. One-fifth of the product was purified by HPLC to afford the titled compound trans-35 (27.8 mg, 43% yield).
26. Nickolls S.A., Cismowski M.I., Wang X., Wolff M., Conlon P.J., and Maki R.A. J. Pharmacol. Exp. Ther. 304 (2003) 1217
27. Chen C., Jiang W., Tucci F.C., Tran J.A., Fleck B.A., Hoare S.R., Joppa M., Markison S., Wen J., Sai Y., Johns M., Madan A., Chen C.W., Marinkovic D., Arellano M., Saunders J., and Foster A.C. J. Med. Chem. 50 (2007) 5249
28. Jiang W., Tucci F.C., Chen C.W., Arellano M., Tran J.A., White N.S., Marinkovic D., Pontillo J., Fleck B.A., Wen J., Saunders J., Madan A., Foster A.C., and Chen C. Bioorg. Med. Chem. Lett. 16 (2006) 4674
29. Based on our previous work, there is only a small (2-fold) affinity difference between the 6-fluorophenylpiperazine and the 4-(trifluoromethyl)phenylpiperazine analogs. See Ref. 6.
30. Tran J.A., Chen C.W., Jiang W., Tucci F.C., Fleck B.A., Marinkovic D., Arellano M., and Chen C. Bioorg. Med. Chem. Lett. 17 (2007) 5165